Novel ATXN1/ATXN1L::NUTM2A fusions identified in aggressive infant sarcomas with gene expression and methylation patterns similar to CIC-rearranged sarcoma

Xu F, Viaene AN, Ruiz J, Schubert J, Wu J, Chen J, Cao K, Fu W, Bagatell R, Fan Z, Long A, Pagliaroli L, Zhong Y, Luo M, Kreiger PA, Surrey LF, Wertheim GB, Cole KA, Li MM, Santi M, and Storm PB. Acta Neuropathologica Communications 10(1): 102, July 2022. doi: 10.1186/s40478-022-01401-z.

Atypical teratoid rhabdoid tumor in a child with neurofibromatosis type 2: A novel dual diagnosis

Kotch C, Fisher M, Zhong Y, Gallo D, Fan E, Lin F, Chen J, Santi M, and Li MM. Cancer Genetics 262–263: 1-4, April 2022. 

A Novel TP53 Tandem Duplication in a Child with Li-Fraumeni Syndrome

Xu F, Aref-Eshghi E, Wu J, Schubert J, Wertheim G, Bhatti T, Pogoriler J, Patel M, Cao K, Long A, Fan Z, Denenberg EH, Fanning EA, Wilmoth DM, Luo M, Conlin LK, Dain AS, Zelley K, Baldino S, Balamuth N, MacFarland S, Li MM, Zhong Y.* Cold Spring Harbor Molecular Case Studies, March 2022.

The oncogenic roles of NTRK fusions and methods of molecular diagnosis

Aref-Eshghi E, Lin F, Li MM, Zhong Y.* Cancer Genetics 258-259: 110-119, Nov 2021.

Application of Next Generation Sequencing in Laboratory Medicine

Zhong Y*, Xu F, Wu J, Schubert J, Li MM. Annals of Laboratory Medicine 41(1): 25-43, Jan 2021.

Genomic characterization of a PPP1CB-ALK fusion with fusion gene amplification in a congenital glioblastoma

Zhong Y^#, Lin F^#, Xu F, Schubert J, Wu J, Wainwright L, Zhao X, Cao K, Fan Z, Chen J, Lang S, Kennedy BC, Viaene AN, Santi M, Resnick AC, Storm PB, Li MM. Cancer Genetics 252-253: 37-42, Dec 2020.

The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: Experience from three pediatric institutions with review of the literature

Lopez-Nunez O, Cafferata B, Santi M, Ranganathan S, Pearce TM, Kulich SM, Bailey KM, Broniscer A, Rossi S, Zin A, Nasrallah MP, Li MM, Zhong Y, Miele E, Alaggio R, Surrey LF. Brain Pathology, 31: 70-83, Sep 2020. doi: 10.1111/bpa.12900.

A Germline PALB2 Pathogenic Variant identified in a Pediatric High Grade Glioma

Zhong Y, Schubert J, Wu J, Xu F, Lin F, Cao K, Zelley K, Luo M, Foster J, Cole KA, Macfarland S, Resnick AC, Storm PB, and Li MM. Cold Spring Harbor Molecular Case Studies 6(4):a005397, Aug 2020. doi: 10.1101/mcs.a005397.

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

Stiff A, Trikha P, Wesolowski R, Kendra K, Hsu V, Uppati S, McMichael E, Duggan M, Campbell A, Keller K, Landi I, Zhong Y, Dubovsky J, Howard JH, Yu L, Harrington B, Old M, Reiff S, Mace T, Tridandapani S, Muthusamy N, Caligiuri MA, Byrd JC, Carson WE 3rd. Cancer Res 76(8): 2125-2136, Apr 2016.

Hypermorphic mutation of phospholipase C, gamma 2 acquired in ibrutinib resistant CLL confers BTK independency upon BCR activation.

Liu TM*, Woyach JA*, Zhong Y*, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Blood 126(1): 61-8, Jul 2015.

Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694

Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA. The Journal of Biological Chemistry 290(10): 5960-78, Mar 2015.

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, Woyach JA, Byrd JC, and Johnson AJ. Blood 124(24): 3583-6, Dec 2014.

Ibrutinib Treatment Ameliorates Murine Chronic Graftversus-Host Disease

Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Yang C, Towns W, Lehman A, Johnson AJ, Muthusamy N, Devine S, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, MacDonald KKP, Maillard I, Koreth J, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR. The Journal of Clinical Investigation 124(11): 4867-76, Nov 2014.

PKC-β as a therapeutic target in CLL: PKC Inhibitor AEB071 Demonstrates Pre-clinical Activity in CLL

El-Gamal D, Williams K, LaFollette T, Cannon M, Blachly J, Zhong Y, Woyach J, Williams E, Awan F, Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, and Byrd JC. Blood 124(9): 1481-91, Aug 2014.

The B-cell Receptor Pathway: A Critical Component of Healthy and Malignant Immune Biology

Zhong Y, Byrd JC, Dubovsky JA. Seminars in Hematology 51(3): 206-18, Jul 2014. 

Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases

Zhong Y*, Johnson AJ, Byrd JC, Dubovsky JA*. Journal of Postdoctoral Research 2(6): 1-11, Jun 2014. 

Selinexor suppresses Downstream Effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells

Zhong Y, El-Gamal D, Dubovsky J, Beckwith K, Harrington B, Williams K, Goettl V, Jha S, Mo X, Jones J, Flynn J, Maddocks K, Andritsos L, McCauley D, Shacham S, Kauffman M, Byrd  JC, and Lapalombella R. Leukemia 28(5): 1158-63, May 2014.

Prolonged Lymphocytosis During Ibrutinib Therapy Is Associated With Distinct Molecular Characteristics and Does Not Indicate A Suboptimal Response To Therapy

Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks J, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. Blood 123(12): 1810-7, Mar 2014.

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Blood 122(15): 2539-49, Oct 2013. 

Selective Inhibitors of Nuclear Export (SINE) show that CRM1/XPO1 is a target in Chronic Lymphocytic Leukemia 

Lapalombella R, Sun Q, Williams Katie, Jha S, Zhong Y, Goettl V, Mahoney E,Berglund C, Alicia F, Rajes M, Johnson AJ, Lucas DM, Mo X, Dirk D, Vincent S, Sharon S, Dilara M, Sharon S, Michael K, Yuh MC, Byrd JC. Blood 120(23): 4621-34, Nov 2012.

AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia

Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM, Kaou M, Zhong Y, Johnson AJ, Lucas DM, Heerema NA, Hagan J, Mo X, Jarjoura D, Byrd JC, Croce CM, Jacob ST. Blood 118(23): 6132-40, Dec 2011. 

Effect of increased HoxB4 on human megakaryocytic development

Zhong Y, Sullenbarger B, Lasky LC. Biochemical and Biophysical Research Communications 398(3): 377-382, Jul 2010.

Search PubMed for articles